Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | CETP | P11597 | 3/20 | 0.46 |
| ▸ | CPA1 | P15085 | 2/20 | 0.43 |
| ▸ | CPB1 | P15086 | 1/20 | 0.43 |
| ▸ | CPA3 | P15088 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14139643 | 0.90 | TSHR (0.45) | TSHRFOLH1CETPCPA1CPB1 | |
| SCHEMBL4634504 | 0.87 | TSHR (0.51) | TSHRFOLH1CETPALDH1A1KMT2A | |
| SCHEMBL17359392 | 0.84 | TSHR (0.49) | TSHRFOLH1CETPALDH1A1NPC1 | |
| SCHEMBL17357042 | 0.82 | TSHR (0.54) | TSHRFOLH1CETPALDH1A1MAPK1 | |
| SCHEMBL13892565 | 0.81 | TSHR (0.56) | TSHRFOLH1CETPALDH1A1NPC1 | |
| SCHEMBL13228165 | 0.81 | TSHR (0.45) | TSHRFOLH1CETPTDP1 | |
| SCHEMBL13892549 | 0.79 | TSHR (0.55) | TSHRFOLH1CETPALDH1A1NPC1 | |
| SCHEMBL10832425 | 0.78 | TSHR (0.62) | TSHRFOLH1CETPALDH1A1KMT2A | |
| SCHEMBL10832590 | 0.76 | TSHR (0.55) | TSHRFOLH1CETPALDH1A1KMT2A | |
| SCHEMBL11303293 | 0.76 | TSHR (0.55) | TSHRFOLH1CETPALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722018-B2 | Method for preparing nanoparticles covered with a gem-bisphosphonate stabilizing layer coupled to hydrophilic distribution ligands | GUERBET (FR) | 2014-05-13 | — | — | US | disclosed |
| US-8722018-B2 | Method for preparing nanoparticles covered with a gem-bisphosphonate stabilizing layer coupled to hydrophilic distribution ligands | GUERBET (FR) | 2014-05-13 | — | — | US | disclosed |
| US-8404664-B2 | Phosphonated Rifamycins and uses thereof for the prevention and treatment of bone and joint infections | TARGANTA THERAPEUTICS, INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-20110263534-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20100215586-A1 | NOVEL METHOD FOR PREPARING NANOPARTICLES COVERED WITH A GEM-BISPHOSPHONATE STABILIZING LAYER COUPLED TO HYDROPHILIC BIODISTRIBUTION LIGANDS | GUERBET (FR) | 2010-08-26 | — | — | US | disclosed |
| US-20100215586-A1 | NOVEL METHOD FOR PREPARING NANOPARTICLES COVERED WITH A GEM-BISPHOSPHONATE STABILIZING LAYER COUPLED TO HYDROPHILIC BIODISTRIBUTION LIGANDS | GUERBET (FR) | 2010-08-26 | — | — | US | disclosed |
| WO-2009053596-A2 | NOVEL METHOD FOR PREPARING NANOPARTICLES COVERED WITH A GEM-BISPHOSPHONATE STABILISING LAYER COUPLED TO HYDROPHILIC BIODISTRIBUTION LIGANDS | GUERBET (FR) | 2009-04-30 | — | — | WO | disclosed |
| US-20060189567-A1 | Compound having affinity with calcified tissue | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1609797-A1 | COMPOUND HAVING AFFINITY WITH CALCIFIED TISSUE | Nihon Medi-Physics Co., Ltd. (JP) | 2005-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189567-A1 | Compound having affinity with calcified tissue | SLC7A1, MBNL1, SHBG | TSHR 879/4885FOLH1 1422/4885CETP 826/4885 |
| US-20100215586-A1 | NOVEL METHOD FOR PREPARING NANOPARTICLES COVERED WITH A GEM-BISPHOSPHONATE STABILIZING LAYER COUPLED TO HYDROPHILIC BIODISTRIBUTION LIGANDS | GMNN, PHOSPHO1, GEMIN4 | TSHR 2745/4885FOLH1 89/4885CETP 383/4885 |
| US-20110263534-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | BPGM, SOST, PSPH | TSHR 4317/4885FOLH1 1237/4885CETP 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.